June 03, 2018
From the Promise of Raising Capital to the Reality of Clinical Trials
2nd Boston ● Paris Biotechnology Summit :
From the Promise of Raising Capital
to the Reality of Clinical Trials
o 25 Expert Speakers including internationally acclaimed Biotechnology Leaders,
o Hear US Expert Opinion from Leaders such as David Meek, CEO of IPSEN; Dr Robert Urban, Global Head of Innovation @ Johnson & Johnson; Dr Mark Murcko, record-holder with 7 drugs developed > taken to Market; Professor Kenneth Kaitin, Tufts CSDD: Center for Study of Drug Development; Dr Joseph Merola, Director of Clinical Trials @ BWH, Harvard Medical School.
o 3 Key notes, 2 Panels, 2 Forums, Entrepreneurs Testimonial, Networking ….
o Over one Hundred Organizations, from a variety of cities, expected at this 2nd Summit.
o Boston-based INVESTORS including nationally highly ranked in life sciences.
o Outstanding opportunity for INTERNATIONAL NETWORKING.
o Program prepared with input from ~20 Expert Advisors including Biogen, Sanofi, Johnson & Johnson Group, Vertex Pharmaceuticals.
For additional Information and to Register please visit http://www.bostonbiotechnologysummit.com/
The Boston– Paris Biotechnology Summit is an exclusive, trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare focused cities, and regional clusters, institutional, philanthropic and strategic investors. The Summits intent is to spark projects, their financings and strategic deals to solve unmet medical needs to improve patients’ lives globally.
© 2018 FACC NEW ENGLAND